Endometrial cancer risk is rising, especially among premenopausal women, with diet and lifestyle factors playing a central ...

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies ...

GlaxoSmithKline Pharmaceuticals has launched Jemperli and Zejula in India, pioneering precision therapies for gynaecological ...

GSK enters oncology with Jemperli & Zejula for gynaecological cancers in India. Advanced therapies address unmet needs in ...

GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision ...

GlaxoSmithKline Pharmaceuticals said it is bringing in Jemperli and Zejula to India, marking its re-entry into the cancer ...

Jemperli is the first and only approved programmed death receptor-1 (PD-1) immunotherapy for the second-line treatment of ...

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast ...

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast cancers are treated in the future ...

In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast ...

Studies show that people receiving tamoxifen, a highly effective and commonly used therapy to treat breast cancer, face a 2- ...